ClinicalTrials.gg
RecruitingNCT06820333Updated Feb 11, 2025

Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer

An observational study in Prostate Cancer (Adenocarcinoma), sponsored by Heinrich-Heine University, Duesseldorf. Recruiting at 1 site in Germany. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Heinrich-Heine University, Duesseldorf · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf — 5 open to participants now, 6 under way, none of them phase 3. Prostatic Neoplasms · Heinrich-Heine University, Duesseldorf.

Started
2025
the only one that year
Observational
4 of 11
3 open now
Registered
10th of 11
by date

Among the 11 studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf, this one is the only one that started in 2025, is one of 4 observational ones, and was the 10th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 11 studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Prostatic Neoplasms by Heinrich-Heine University, Duesseldorf, or all of them as a file.
02

Study summary

The introduction of PSMA diagnostics and therapy has fundamentally changed the treatment management of prostate cancer and has significantly replaced other clinical and radiological diagnostic methods. As a result, 18F-PSMA-1007 (Radelumin®) was approved in Germany and several EU countries, most recently in Germany in 01/2024, for use in primary staging of high-risk prostate cancer and re-staging in the context of biochemical recurrence (BCR). This could be seen as a milestone in the management of prostate cancer and will significantly promote the widespread use of PSMA-PET diagnostics in the coming years.

The investigators now intend to prospectively generate evidence-based data in everyday clinical practice with this so-called Real-World-Evidence (RWE) study. The planned study will enable us to analyze the diagnostic accuracy of Radelumin® in more detail under everyday conditions, whereby dedicated examinations of certain subgroups and the prospective generation of a complete, high-quality database for the future use of artificial intelligence (AI) will be made possible.

Read the detailed description

Depending on the study design and definition of the patient population, the detection rate of pelvic lymph nodes in particular using PSMA imaging is reported to be >80%. The results of the studies thus demonstrate a superior diagnostic accuracy compared to previous methods as well as a significant influence of PSMA imaging on the clinical course. Radelumin® was approved on the basis of these promising results from numerous retrospective studies and the prospective, randomized approval study.

Nevertheless, it should be noted that the results derived from such data generally deviate from the data in everyday clinical practice for various reasons. Furthermore, the retrospectively planned studies show multiple general weaknesses, whereby the prospective randomized approval studies also show a priori weaknesses. These result from a very limited observation phase and the lack of long-term data, despite good planning with a high power, a small number of patients and the targeted homogeneity of the patient population. In the context of a real-world evidence study, which focuses on routine clinical care, the above-mentioned disadvantages are compensated for by long-term observation, a considerably larger patient population and a realistic patient mix.

03

Conditions studied

  • Prostate Cancer (Adenocarcinoma)

Keywords

  • PSMA
  • PSMA-PET
  • PSMA PET/CT
  • Primary Staging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

biologically male patients with biopsy-proven or highly suspected prostate cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 18 years
  • Planned [18F]PSMA-1007 PET/CT examination in patients with a first diagnosis of prostate cancer

Exclusion criteria

Exclusion Criteria:

  • Examinations with limited assessability due to technical errors, such as imaging artifacts.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Diagnostic Accuracy and Prognostic Value of [18F]PSMA-1007 PET/CT in Primary Staging of Prostate Cancer

    1. The primary outcome will assess the diagnostic accuracy of \[18F\]PSMA-1007 PET/CT by comparing its sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) against histopathological confirmation or composite clinical follow-up as the reference standard. 2. The prognostic value will be evaluated by analyzing the association between baseline PSMA PET/CT-derived parameters (e.g., SUVmax, tumor burden, lesion distribution) and oncological outcomes, including biochemical recurrence-free survival and progression-free survival. 3. Quantitative PET parameters will be extracted using a standardized semi-automated segmentation method, and survival analysis will be conducted using Kaplan-Meier estimates and Cox proportional hazards models.

    Time frame: Interim analyses will be performed annually, with a final analysis at 5 years.

Secondary outcomes

  1. Correlation of PET Parameters with Clinical and Pathological Features Description

    1. The correlation between PET-derived quantitative parameters (SUVmax, metabolic tumor volume \[MTV\], total lesion PSMA expression \[TLPE\]) and clinical/pathological factors (Gleason Score, PSA level, tumor stage, lymph node involvement) will be assessed. 2. The proportion of patients whose management plan (e.g., radical prostatectomy, radiotherapy, systemic therapy) changed due to PSMA PET/CT findings compared to conventional imaging. Measured by documenting pre- and post-imaging treatment plans and analyzing changes in therapeutic strategies. 3. The relationship between baseline PSMA PET/CT findings and biochemical recurrence free survival (BRFS) will be analyzed using Kaplan-Meier survival analysis and Cox proportional hazards modeling.

    Time frame: Evaluated at 1-year, 2-year, and 5-year follow-up.

07

Study locations

1 of 1 sites recruiting
  • Heinrich Heine University, Medical Faculty, University Hospital Düsseldorf
    Duesseldorf, NRW 40225, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — At a reasoble request, the study data would be provided.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2030, 60 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 60 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Feb 11, 2025
StartActual
Jan 10, 2025
Primary completionEst.
Jan 31, 2030
CompletionEst.
Jan 31, 2030
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06820333
Responsible party
Dr. med. Emil Novruzov (Dr. med., Heinrich-Heine University, Duesseldorf) — Principal investigator
First posted
Feb 11, 2025
Start date
Jan 10, 2025
Primary completion
Jan 31, 2030 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Feb 11, 2025

Study contacts

Emil Novruzov, Medical Doctor
Contact
Emil.Novruzov@med.uni-duesseldorf.de
(+49)211 8118540
Eduards Mamlins, Medical Doctor
Contact
eduards.mamlins@med.uni-duesseldorf.de
(+49)211 8108069
Frederik Lars Giesel, Prof. Dr., Medical Doctor
study chair · Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion